UNITY Biotechnology Announces Positive Results in Phase 2 BEHOLD Study of UBX1325 for Diabetic Macular Edema DME
On April 24, 2023, UNITY Biotechnology made an exciting announcement regarding the Phase 2 BEHOLD study of UBX1325. The study ...
Tag: UBX
UNITY Biotechnologys Phase 2 ENVISION Study Shows Promising Results for AgeRelated Macular Degeneration Treatment
UNITY Biotechnology has recently released the findings from Part A of the Phase 2 ENVISION study, which focused on evaluating ...